E6(R3): Beyond Compliance in Vendor Oversight

Oversight is no longer periodic or document-driven.
It must be continuous, risk-based, and fully traceable across vendors, studies, and services.

Yet most pharma organizations still operate with:

• fragmented systems
• manual workflows
• limited visibility

👉 That’s where control breaks down.

🚨 Why This Matters Now

E6(R3) does not change accountability - it changes how oversight must be demonstrated.

Sponsors are now expected to:

• continuously monitor vendor risk
• ensure decision traceability
• maintain structured governance across the lifecycle

This exposes a critical gap:

👉 Vendor management processes don’t scale to E6(R3) expectations

At this level of complexity, this is no longer a process issue - it’s a systems and orchestration challenge.

🎯 Join the Webinar

📅 20 May 2026 | 12 PM EST

📍 LinkedIn Live

A practical, experience-driven session on what vendor oversight looks like in reality — not theory.

👉 Register Now

👥 Speakers

Anca Copaescu
CEO, Clinical Maestro

Sameer Tandon
Senior Director, R&D Strategic & Innovative Transactions
Bristol Myers Squibb

Andrei Antonescu
Head of Product, Clinical Maestro

🔍 What You’ll Learn

⚠️ Risk — From Identification to Continuous Monitoring

• Why risks are recognized too late
• Limits of periodic and manual assessments
• Moving to continuous, trigger-based monitoring

🧾 Compliance — Inspection Readiness & E6(R3)

• What E6(R3) requires in practice
• From documentation to decision traceability
• Why most organizations are not fully prepared

📊 Performance — From KPIs to Decision Support

• Why traditional KPIs fail
• Connecting performance with risk and outcomes
• Moving to real-time, actionable insights

🧠 Orchestration — Connecting Everything

• Why fragmented tools don’t scale
• The need for a single source of truth
• Structured workflows and end-to-end visibility

🎯 Sponsor Perspective — Reality at Scale

• Managing vendor complexity in large pharma
• Trade-offs between speed, cost, and compliance
• What actually works — and what doesn’t

🧠 What Makes This Different

This is not a product demo.

This is not a theoretical discussion.

You will hear:

• real challenges from large pharma
• practical insights grounded in operations
• how organizations are evolving toward structured oversight

🚀 Who Should Attend

• Clinical Operations Leaders
• Vendor Management / Outsourcing Heads
• Procurement & TPRM Teams
• Quality & Compliance Leaders
• Pharma & Biopharma Executives

👉 Secure Your Spot

If you are responsible for vendor oversight in clinical trials, this session will help you understand:

• where your current approach may fall short
• what E6(R3) means operationally
• how to move toward scalable, structured oversight

👉 Register Now